Search - tctmd.com

Displaying 21 - 40 of 79

Sort: Relevancy | Date

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for September 2022

Shelley Wood

October 03, 2022

News Opinion Editor's Corner ESC 2022

What’s Going to Be Hot at ESC 2022?

Shelley Wood

August 22, 2022

News Daily News

Desperate for Relief, Long COVID Patients Seek Apheresis, Other Untested Therapies

Todd Neale

July 14, 2022

News Conference News ACC 2022

Managing AF Patients Undergoing PCI—Some Lingering Questions

Michael O'Riordan

April 12, 2022

News Daily News

Subclinical Leaflet Thrombosis After TAVI Linked to Higher Mortality

Michael O'Riordan

March 10, 2022

News Daily News

Fewer Diabetic Complications Seen When NOACs Given for AF

L.A. McKeown

February 22, 2022

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for January 2022

Shelley Wood

January 31, 2022

News Daily News

DOACs Should Be Standard to Prevent VTE Recurrence in Cancer: Meta-analysis

L.A. McKeown

January 20, 2022

News Daily News

USPSTF at Last Takes Tougher Stance on Aspirin in Primary Prevention

Shelley Wood

October 15, 2021

Antithrombotic therapy does not provide a benefit for clinically stable but symptomatic outpatients with COVID-19, published results of the ACTIV-4b trial affirm. Neither aspirin nor apixaban (Eliquis; Bristol Myers Squibb) at prophylactic or therapeutic doses reduced what were already very low rates of major adverse cardiopulmonary outcomes versus placebo, and both modestly increased bleeding, researchers led by Jean Connors, MD (Brigham and Women’s Hospital, Boston, MA), report in a paper published online

News Daily News

ACTIV-4b: No Antithrombotic Therapy Needed for COVID-19 Outpatients

Todd Neale

October 13, 2021

News Daily News

COVID-19: TCTMD’s Dispatch for October Week 2

Todd Neale

October 11, 2021

News Daily News

Therapeutic-Dose Heparin in COVID-19: Who Benefits, Who Doesn’t

Shelley Wood

August 04, 2021

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for May 2021

Shelley Wood

May 31, 2021

News Conference News ACC 2021

Apixaban Curbs Subclinical Thrombosis After TAVI in Patients Without Prior OAC

Michael O'Riordan

May 17, 2021

News Daily News

Observational Study Supports Continuing Oral Anticoagulation During PCI

Michael O'Riordan

April 06, 2021

News Daily News

Antithrombotic Therapy for COVID-19: Challenges and Lessons for the Future

L.A. McKeown

March 17, 2021

News Daily News

Systemic Anticoagulation Linked to Lower Mortality in Hospitalized COVID-19

Michael O'Riordan

August 28, 2020

News Daily News

How COVID-19 Promotes Thrombosis, Posing Problems for Drug-Drug Interactions

Michael O'Riordan

April 22, 2020

News Daily News

New Meta-analysis Supports NOAC Plus P2Y12 Inhibitor for PCI in A-fib

Shelley Wood

February 28, 2020

News Opinion Editor's Corner

The Biggest News of 2019: TCTMD’s Top 10

Shelley Wood

January 01, 2020

Advertisement

TCTMD’s Top 10 Most Popular Stories for September 2022

What’s Going to Be Hot at ESC 2022?

Desperate for Relief, Long COVID Patients Seek Apheresis, Other Untested Therapies

Managing AF Patients Undergoing PCI—Some Lingering Questions

Subclinical Leaflet Thrombosis After TAVI Linked to Higher Mortality

Fewer Diabetic Complications Seen When NOACs Given for AF

TCTMD’s Top 10 Most Popular Stories for January 2022

DOACs Should Be Standard to Prevent VTE Recurrence in Cancer: Meta-analysis

USPSTF at Last Takes Tougher Stance on Aspirin in Primary Prevention

ACTIV-4b: No Antithrombotic Therapy Needed for COVID-19 Outpatients

COVID-19: TCTMD’s Dispatch for October Week 2

Therapeutic-Dose Heparin in COVID-19: Who Benefits, Who Doesn’t

TCTMD’s Top 10 Most Popular Stories for May 2021

Apixaban Curbs Subclinical Thrombosis After TAVI in Patients Without Prior OAC

Observational Study Supports Continuing Oral Anticoagulation During PCI

Antithrombotic Therapy for COVID-19: Challenges and Lessons for the Future

Systemic Anticoagulation Linked to Lower Mortality in Hospitalized COVID-19

How COVID-19 Promotes Thrombosis, Posing Problems for Drug-Drug Interactions

New Meta-analysis Supports NOAC Plus P2Y12 Inhibitor for PCI in A-fib

The Biggest News of 2019: TCTMD’s Top 10

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content